Boundless Bio (BOLD) Enterprise Value (2023 - 2026)

Boundless Bio (BOLD) has reported Enterprise Value for 4 consecutive years, with -$92.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Enterprise Value rose 32.84% year-over-year to -$92.8 million; the TTM figure through Mar 2026 stood at -$92.8 million (up 32.84% YoY), while the FY2025 annual figure was -$107.6 million, up 29.28% from the prior year.
• Enterprise Value advanced to -$92.8 million in Q1 2026 per BOLD's latest filing, from -$107.6 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$21.0 million in Q3 2023 and bottomed at -$220.2 million in Q3 2025.
• Historically, Enterprise Value has averaged -$114.9 million across 4 years, with a median of -$120.8 million in 2023.
• Annual changes were most pronounced in 2024 — Enterprise Value tumbled 697.25% — and 2026, when it soared 32.84%.
• Boundless Bio's Enterprise Value stood at -$120.8 million in 2023, then slipped by 25.97% to -$152.1 million in 2024, then gained by 29.28% to -$107.6 million in 2025, then grew by 13.7% to -$92.8 million in 2026.
• Business Quant data shows BOLD's Enterprise Value at -$92.8 million in Q1 2026, -$107.6 million in Q4 2025, and -$220.2 million in Q3 2025.